Lucid Diagnostics (LUCD) Shares Outstanding (Weighted Average) (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $140.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 103.64% year-over-year to $140.1 million; the trailing twelve-month figure through Mar 2026 stood at $140.1 million (up 103.64% YoY), and the FY2025 full-year result was $101.9 million, up 101.81% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $140.1 million, up from $101.9 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $140.1 million in Q1 2026 and bottomed at $35.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $45.0 million (2024), against an average of $59.0 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) jumped 153.41%; it then climbed 9.87% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $36.2 million in 2022, then climbed by 15.44% to $41.8 million in 2023, then gained by 20.98% to $50.5 million in 2024, then soared by 101.81% to $101.9 million in 2025, then jumped by 37.42% to $140.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $140.1 million (Q1 2026), $101.9 million (Q4 2025), and $92.1 million (Q3 2025), per Business Quant data.

Peer Comparison